Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/tumor-immunology-immunotherapy-and-cancer-vaccines/dalgleish/descriptif_1416172
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=1416172

Tumor Immunology Immunotherapy and Cancer Vaccines Cancer: Clinical Science in Practice Series

Langue : Anglais

Coordonnateurs : Dalgleish A. G., Browning M. J.

Préfacier : Sikora Karol

Couverture de l’ouvrage Tumor Immunology
This 1996 volume reviewed advances in the field of human tumour immunology for an audience of clinicians and researchers.
This 1996 volume reviewed advances in the field of human tumour immunology, particularly in relation to the potential for immune intervention in preventing or treating tumours. The editors and contributors, all prominent workers in the field, survey advances in the understanding of the relationship between the cancer cell and the immune response at the time of publication. Chapters review in depth the function of immune surveillance and mechanisms of tumour immunity, the role of T lymphocytes and oncogenes in the immune response to cancer, and the potential for immunotherapy of cancer. Areas of tumour immunology that were new at the time of this book's publication are presented, including progress in the development of tumour vaccines with particular reference to melanoma. The volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.
Contributors; Series Editor's Preface; Abbreviations; 1. Introduction and historical perspectives Michael Browning and A. G. Dalgleish; 2. The immunosurveillance of cancer: specific and non-specific mechanisms Richard G. Vile, Heung Chong and Sina Dorudi; 3. Antigen processing and presentation Nicholas C. Testifo and Michael Wang; 4. The role of the MHC class I in tumor immunity Michael Browning; 5. Human tumor antigens recognized by Cytolytic T Lymphocytes Pierre G Coulie; 6. Peptide-specific CTL directed against viral oncogene products Mariet C.W. Feltkamp, Cornelis J. M. Melief and W. Martin Kast; 7. Cellular oncogenes for tumor immunity: immunotherapy Hans J. Strauss and A. Maria Dahl; 8. Co-stimulatory molecules and their role in tumour immunity A. G. Dalgleish; 9. The role of cytokines in tumour rejection Guido Forni and Robin Foa; 10. Inhibition of nonhemopoietic cancer cell growth by Interleukin-4 and related cytokines Dave S. B. Hoon, Takashi Morisaki and Richard Essner; 11. Current concepts concerning melanoma vaccines Donald L. Morton and Mepur H. Ravindranath; 12. Immune responses to mucins Rosalind A. Graham and Joyce Taylor-Papadimitriou; 13. Heat shock protein-peptide complexes: pan-valent vaccines against cancers and infectious diseases Ryuichiro Suto and Pramod K. Srivastave; 14. The potential of gene transfer to alter the immune response to tumors Bernard A. Fox and Gary J. Nabel; 15. Applications of antibody gene technology Robert E. Hawkins and Kerry A. Chester; Index.
The concept of tumor immunogenicity has been around for almost as long as the study of immunology itself, and recent years have seen significant advances in the field of human tumor immunology. The purpose of this volume is to review these advances, particularly in relation to the potential for immune intervention in preventing or treating tumors. The editors and contributors, all leading workers in the field, survey advances in the understanding of the relationship between the cancer cell and the immune response. Chapters review in depth the function of immune surveillance and mechanisms of tumor immunity, the role of T lymphocytes and oncogenes in the immune response to cancer, and the potential for immunotherapy of cancer. New areas of tumor immunology are presented, including recent p

Date de parution :

Ouvrage de 374 p.

15.2x22.9 cm

Disponible chez l'éditeur (délai d'approvisionnement : 14 jours).

Prix indicatif 54,78 €

Ajouter au panier

Thème de Tumor Immunology :